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Abstract  
AIM: This study aimed to compare the effect of Imipenem monotherapy and combination therapy with 
Ceftazidime/Amikacin in febrile episodes in neutropenic cancer patients. 
MATERIALS AND METHODS: In this double-blind randomised trial, 122 adult patients with cancer, neutropenia 
and fever who were treated by chemotherapy were gathered by simple sampling method and were divided 
randomly to two equal Imipenem (IP) and Ceftazidime/Amikacin (CA) groups. 500 mg of Imipenem was 
administered every 6 hours IP group and 2 g of Ceftazidimeplus 15 mg/kg/day in 2 equally divided doses of 
Amikacin was administered in the CA group. The treatment was continued for 72 hours in both groups. Data were 
analysed with SPSS19. 
RESULTS: There was a significant difference between the mean temperatures of three days in each group (P < 
0.001). There was no significant difference between the two groups regarding microbial response to antibiotics. 
There was no significant difference between 19 patients of IP and 13 patients of CA groups regarding 
bacteriologically documented infection (P = 0.3). 
CONCLUSION: Unmodified therapy by Imipenem is as effective as combinational therapy by 
Ceftazidime/Amikacin in clinically and bacteriologically documented infection. 
 
 
 
 
 
 
 
 
 
Introduction 
 
Cancer is the second leading cause of death 
after heart disease [1] [2]. Cancer patients are 
susceptible to neutropenia following chemotherapy. 
One of the complications of chemotherapy is a fever 
in neutropenic patients. Neutropenia is a medical 
emergency [3] [4] [5]. Fever occurs in 10-50% of 
patients with solid tumours and more than 80% of 
patients with haematological malignancies during 
chemotherapy-induced neutropenia [6] [7]. 
Bacteremia can occur in 10-25% of all patients, 
especially at neutrophil levels below 100 cells/μl. 
Gram-negative bacteria resistant to the drug increase 
the risk of infection in patients with febrile neutropenia 
[9]. In the initial assessment of fever, blood collection 
of all catheter lumens (if present) is important as a 
culture of the peritoneal vein in the patient with 
neutropenic cancer [11]. Choosing the right antibiotic 
in patients with neutropenic fever can effectively 
improve survival and quality of life and reduce the cost 
of treatment in health centres. No specific drug or 
drug combination cannot be recommended to all 
patients for the treatment of neutropenic fever. 
There is no consensus to manage fever and 
neutropenia in cancers, which can be due to several 
factors including the emergence of new risk factors in 
hosts with reduced immunity, changes in the 
epidemiology of infections, increased bacterial 
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resistance, and treatment costs [12] [13]. The 
combination of amikacin and ceftazidime is 
considered as a standard treatment. Ceftazidime is 
widely used in this field, and the effect of its 
combination with aminoglycosides has been applied in 
the treatment of neutropenic fever [11]. Imipenem can 
be used as a single drug and has been very effective 
in controlling infection in neutropenic patients due to 
its wide-ranging bactericidal properties. Imipenem is 
an intravenous β-lactam antibiotic that has a 
nephrotoxic potential. Today, imipenem is widely used 
as a broad-spectrum antibiotic in the first line of 
treating fever and neutropenia in patients with cancer 
[14]. 
Previous studies have reported that the 
efficacy of ceftazidime in the treatment of fever and 
neutropenic was 44% and 41% respectively [15], 
while in other studies, the efficacy of ceftazidime and 
amikacin were determined to be similar [16] [17] [18] 
[19] [20] [21] [22]. However, it has been demonstrated 
that the use of imipenem is superior to ceftazidime in 
the treatment of chemotherapy-induced febrile 
neutropenia [15]. It has been revealed that the 
efficacy of meropenem in comparison with the 
combination of ceftazidime and amikacin did not have 
any significant difference [20] [23]. While a similar 
study depicted that, the use of meropenem in the 
treatment of fever and neutropenia was more effective 
than combination therapy of ceftazidime and amikacin 
[21] [22] [23]. Since our country is different regarding 
climate, economic, antibiotic availability and possibly 
the type of microbial flora with other countries, 
revision of the studies undertaken by other countries 
is necessary because the selection of these regimes 
in each region and even in each hospital is unique. 
Few studies have been done on the therapeutic effect 
of imipenem, ceftazidime/amikacin. Imipenem also 
has a high price compared to ceftazidime/amikacin. 
Reducing the monetary burden on patients and the 
state is important in treating the disease. Furthermore, 
the continued use of a high-value, broad-spectrum 
antibiotic by the most physician is a factor in the 
development of drug resistance in organisms that give 
the drug a good response.  
This study aimed to determine predominant 
germs in patients with febrile neutropenia and to 
determine the antibiotic resistance in febrile 
neutropenic cancer patients. Also, patients' responses 
to these two drug regimens were investigated to help 
clinicians decide on appropriate treatment for this 
condition [23]. 
 
 
Material and Methods 
 
In this interventional study, 122 patients with 
neutropenic fever who referred to Khansari Hospital in 
Arak were enrolled in the study. Inclusion criteria 
include a person less than or equal to 18 years old 
with cancer (a hematologic or a solid tumour), 
Patients undergoing chemotherapy, Oral temperature 
>38.3°C or > 38°C for one hour, neutrophil count 
below 1500 μL, satisfaction to participate in the study. 
Exclusion criteria include pregnancy, lactation, and 
antibiotic intake at least three days before the study, 
history of pneumonia or anaphylaxis with antibiotics 
studied, patients with history of seizure, localized 
leukemia and central nervous system infection, cystic 
fibrosis, liver and kidney failure, aplastic crisis, coma, 
septic shock, bone marrow transplantation, acquired 
immunodeficiency virus, fever with a specific origin. 
To validate the hypotheses and analysis of 
the symptoms, if patients were diagnosed with 
another episode of fever and neutropenia, patients 
have not re-entered the study. Patients were randomly 
divided into two groups. The first group received 500 
milligrams of imipenem (built in Iran) intravenously 
every 6 hours (at 100 ccs normal saline diluted) in 30 
minutes. For the second group, 2 g of ceftazidime 
(made in Iran) every 8 hours (in 100 ml of normal 
saline) was intravenously used over 30 minutes and 
immediately followed by amikacin therapy (15 mg) 
twice a day.  
Before administration of antibiotics, all eligible 
patients underwent an initial assessment including 
history, physical examination, and culture from any 
potential site of infection (e.g., blood culture, oral and 
urinary tract). Laboratory tests included complete 
blood count (CBC), Na, K, blood urea nitrogen (BUN), 
Cr, Ca, aspartate aminotransferase (AST), Alanine 
aminotransferase (ALT), alkaline phosphatase (Alk-p), 
Bilirubin. Patients were checked daily for the presence 
of fever, and the patient's body temperature was 
recorded accurately by using a mercury thermometer. 
All patients in both groups were evaluated for 
response to treatment after 72 hours of antibiotic 
therapy. Clinical confirmation of infection is defined as 
Clinical evidence of infection with or without 
microbiological confirmation. Bacteria are defined as 
fever and at least one positive blood culture. Clinical 
response to treatment included fever in the patient. 
If the symptoms of the infection were resolved 
without modification in the diet, it was considered an 
improvement. Moreover, the condition was classified 
as a treatment failure, if the symptoms were not 
changed or worsened, or even the signs of infection 
improved by changing the antibiotic regimen or the 
occurrence of death following infection. 
On the third day, blood and urine culture was 
performed from patients to assess the bacteriological 
response to treatment. The bacteriological response 
for all infections was measured by comparing the 
cultures before treatment with post-treatment cultures. 
The positive bacteriological response is defined as 1: 
Eradicating which pathogens are eliminated on the 
treatment lines. 2: Eradicating with potentially strong, 
where appropriate principles for cultivation are not 
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available, but the patient has a satisfactory clinical 
response. The failure of the bacteriological response 
is defined as 1 - Continuity means the removal of 
some or all of the pathogens before treatment. 2 -
Failure with a high probability where positive culture is 
unavailable, but the clinical signs of infection in the 
patient persist or worsen. In patients who responded 
to treatment, we continued treatment for up to 7 days 
or 4 days after the fever. If after 72 hours, the fever 
did not stop, another drug was added for treatment, 
and the patient was excluded from the study. 
Death in the first three days of treatment was 
considered as treatment failure for clinical and 
bacteriological responses. Patients were regularly 
evaluated for adverse drug-related side effects. 
Before starting an antibiotic, three blood samples, 
urine culture, stool culture, and catheter tip were 
obtained from each patient. Mac Conkey agar and 
blood agar were used in this study, followed by urine 
culture (Chocolate agar), blood cultures (Mac Conkey 
agar and xld agar), stool culture (Thioglycolate), and 
catheter tip (elemental environment) all of which were 
made by CONDA. 
An antibiogram test was performed, where 
antibiotic disks containing imipenem (with 10 μg per 
disk) and ceftazidime (30 μg per disk) and amikacin 
(30 μg per disk) (antibody medicine, Iran) were placed 
on the medium, followed by incubation in 37°C for 24 
hours. 
After 24 hours, the diameter of the inhibition 
zone was measured. The susceptibility and resistance 
of isolated microbes from culture media were 
determined based on the diameter of the inhibition 
zone (mm).  
Data were analysed by SPSS 19 software. 
The Independent Samples t-Test was applied to 
compare the means of two independent groups for 
data with normal distribution, and the Mann-Whitney 
test was used in the absence of normal distribution. 
 
 
Results 
 
In this study, 122 patients with neutropenic 
fever were studied in cancer patients. Of these, 68 
(55.7%) were male, and 54 (44.3%) were female. The 
mean age of the imipenem group was 49.9 (SD: 
11.73), and the mean age of the Ceftazidime / 
Amikacin group was 43.36 (SD: 11.65), with a 
significant difference between the two groups (P = 
0.002). The underlying disorders of the patients were 
as follows; leukaemia: 50 subjects (41%), lymphoma: 
24 (19.7%), solid tumour: 38 subjects (31.1%), 
myelodysplastic syndrome: 7 subjects (5.7%). There 
was no significant difference between the two groups 
regarding the distribution of underlying disease (P = 
0.93). All patients entering the study had a 
temperature of more than 38.3°C on the first day. The 
average body temperature on the first day in the 
imipenem group was 39.08 (SD: 0.22), while it was 
determined to be 39.2 in the ceftazidime/amikacin 
group (SD: 0.25), which depicted a significant 
difference between the two groups in terms of mean 
fever on the second and third days (P = 0.004). Of all 
patients entering the study, 17 (13.9%) were febrile on 
the third day, 7 (11.5%) were in the imipenem group 
and 10 (16.4%) in the ceftazidime/amikacin group. 
There was no significant difference between the two 
groups regarding the number of discontinuation of 
fever in the two groups (P-value = 0.60). In this study, 
the neutrophil count was mild in 19 patients (15.6%), 
followed by medium neutrophilia in 80 subjects 
(65.6%), severe neutrophilia in 23 patients (18.9%). 
There was no significant difference between the levels 
of neutrophil in the first day (P = 0.20) and the third 
day (P = 0.13) between the two groups. On the third 
day, 13 patients (10.7%) had neutrophil levels below 
500 cells/μl. Twelve patients (52.2%) with severe 
neutropenia remained febrile on the third day, of 
which 5 subjects (38.5%) belonged to the imipenem 
group, and 7 subjects (70%) were assigned into 
ceftazidime/amikacin group. There was no significant 
difference in fever on the third day in both groups (P = 
0.21). Furthermore, 21 patients (17.2%) had positive 
blood culture on the first day. No significant difference 
was found between the two groups regarding positive 
blood culture (P-value = 0.63). 
Seventy patients (33.3%) had positive blood 
culture on the third day, where 3 (25%) patients 
belonged to the imipenem group, while 4 subjects 
(44.4%) belonged to ceftazidime/amikacin group. No 
significant difference was found between the two 
groups regarding positive blood culture on day 3 
(p=0.39). Moreover, sixteen patients (13.1%) had a 
positive urine culture on the first day. There was no 
significant difference between the two groups 
regarding positive urine culture in the first day 
(p=0.78), while 100% of patients had a negative urine 
culture on day 3. No patient showed any positive stool 
culture. One patient (1.6%) had a positive catheter tip 
culture, where it was observed in the imipenem group. 
There was no significant difference between the two 
groups regarding the catheter tip culture at day 1 (P = 
1.00). The catheter culture of this patient remained 
positive on the third day. 
Out of 21 patients who had positive blood 
culture on the first day, 5 patients (23.8%) showed 
Staphylococcus epidermidis, Followed by the 
presence of Staphylococcus aureus (9.5%; 2 
patients), Escherichia coli (57.1%; 12 patients) and 
Pseudomonas aeruginosa (9.5%; 2 patients). There 
was no significant difference between the two groups 
regarding bacterial isolation from the blood on the first 
day (P = 0.77). Blood culture in the third day of 
patients with gram-negative organisms (E. coli and 
Pseudomonas spp.) was negative. Blood cultures of 
all patients with Gram-positive organisms (S. aureus 
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and S. epidermis) remained positive on day 3. No 
significant difference was observed between the two 
groups regarding the type of bacteria isolated from 
blood culture on day 3 (P = 0.90). 
It is worth noting that the only bacterial 
species isolated from urine culture was Escherichia 
coli. We did not observe a significant difference 
between the two groups regarding bacterial isolation 
from the urine (P-value = 0.78). The only bacteria 
isolated from the catheter tip culture were S. aureus. 
In 16 patients, we had to modify the type of antibiotic. 
Vancomycin was added to the regimen of 14 patients 
(87.5%), of which 5 patients (83.3%) belonged to the 
imipenem group and 9 subjects (90%) was observed 
in the ceftazidime/amikacin group. Two patients 
(12.5%) also received amphotericin, of which 1 patient 
(16.7%) was determined to belong to the Imipenem 
group, and 1 patient (10%) was observed in the group 
of ceftazidime/amikacin. Therefore, no significant 
difference was found between the two groups 
regarding the need for drug modification (P = 1.00). 
Bacteriologic infection was confirmed in 32 patients 
(26.2%) during episodes of fever, of which 19 patients 
(31.1%) were in the imipenem group and 13 patients 
(21.3%) in the ceftazidime/amikacin group. There was 
no significant difference in bacteriological infection 
between the two groups (P = 0.30). 
The clinical response of patients to antibiotics 
was divided into three groups: 1) fever reduction 
occurred in 105 patients (86.1%), of which 54 patients 
(88.5%) in the imipenem group and 51 patients 
(83.6%) in the ceftazidime/Amikacin; 2) improvement 
with antibiotic adjustment occurred in 16 patients 
(13.1%), of which 6 subjects (9.8%) were in the 
Imipenem group, and 10 patients (16.4%) were 
observed in the group of ceftazidime/amikacin; and 3) 
death occurred in one patient (1.6%) in the imipenem 
group. 
There was no significant difference between 
the two groups regarding clinical response to 
antibiotics (P-value = 0.35). 
Of the 38 patients with positive microbial 
culture, 29 (80.6%) had a positive microbial response 
to antibiotics. 
 The results were negative on the third day, of 
which 18 patients (85.7%) were in the Imipenem 
group, and 11 patients (73.3%) were in the 
ceftazidime/amikacin group. There was no significant 
difference between the two groups regarding microbial 
culture response to an antibiotic (P = 0.41). Imipenem 
was more effective than ceftazidime/amikacin 
reducing fever and improving clinical symptoms of 
patients with and without bacteriological confirmation. 
However, there was no significant difference between 
the two groups. Both drugs were more effective in 
patients with bacteriological confirmation than non-
bacteriologic confirmation. 
Nevertheless, there was no significant 
difference between the two groups. No side effects 
were seen in any of the patients. Because the fever 
values were measured in three consecutive periods in 
two groups, advanced analysis of the repeated 
measurements analysis has been used. Using this 
analysis, there was a statistically significant difference 
between the mean fever in three periods (P < 0.001), 
but there is no significant difference between the 
mean fever in the three consecutive periods in the two 
groups. 
Imipenem was depicted to be more effective 
than ceftazidime/amikacin in clinical improvement and 
fever reduction. However, no significant difference 
was observed in the two groups. Also, ampicillin was 
more effective than ceftazidime/amikacin in clinical 
improvement and fever reduction in patients with 
severe neutropenia, but no significant difference was 
found between the two groups. 
Table 1: Demographic and statistical information in two 
intervention groups 
P-value Ceftazidime and 
amikacin 
Imipenem Group / variable 
....0 (0.25)02.9. 0.22))02..3 Body temperature of the first day (SD) 
...0  (1.01)06.70  (0.93)06.70 Body temperature of the second day (SD) 
...2 (0.96)06.0. (0.72)06..2 Body temperature of the third day (SD) 
..9. )9..0%(.0 )2.3%( 1000-1500 Neutrophil counts on 
the first day )79.0%(03 )73.2%(09 500-1000 
).7.0%(.. )9..0%(.0 <500 
...0 )90.7%(1. ).0..%(3 1000-1500 Neutrophil counts on 
the third day )79.0%(03 )63.6%(03 500-1000 
).0..%(3 )3.9%(1 <500 
..9. )6.%(6 )03.1%(1 >03.0 Body temperature on
day 3 in patients with 
neutrophil counts 
below 500 
)0.%(0 )7..1%(3 <06.9
..70 )3..0%(2 ).2.6%(.9 Positive Blood culture on the 
first day )31.9%(19 ).0.3%(02 Negative 
..02 )00.0%(0 )91%(0 Positive Blood culture on the 
third day )11.7%(1 )61%(2 Negative 
..63 )...1%(6 ).0.3%(2 Positive Urinary culture on 
the first day )33.1%(10 )31.9%(19 Negative 
_  (...)%6  (...)%2 Negative Urinary culture on 
the third day 
_  (...)%7.  (...)%7. Negative First day stool 
culture 
.... )...%(. )..7%(. Positive The first day of the 
catheter tip culture )...%(7. )23.0%(7. Negative 
_ _ )...%(. Positive The third day of the 
catheter tip culture 
..0. )97.99%(.7 )07..7%(99 With bacteriological 
confirmation 
Tabs episode 
classification 
)60.66%(01 )70.20%(02 No bacteriological 
confirmation 
..01 )30.7%(1. )33.1%(10 Stop the fever Clinical response to 
antibiotics 
 ).7.0%(.. )2.3%(7 Improve with 
antibiotic change 
 
)...%(. )..7%(. Death 
..0. )60.0%(.. )31.6%(.3 Positive Microbial culture 
response to 
antibiotics 
)97.6%(0 ).0.0%(0 Negative 
0.77  (.1.03)%7  (...09)%0 >03.0 Body temperature on 
day 3 in patients 
without 
bacteriological 
confirmation 
 (30.7.)%00  (33.16)%0. <06.9 
 
None of the Gram-positive bacteria was 
susceptible to three antibiotics. One hundred per cent 
of the gram-negative bacteria were sensitive to 
imipenem and ceftazidime, and 86.6% were sensitive 
to amikacin. Both P. aeruginosa and two E. coli blood 
cultures were resistant to amikacin. 
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Figure 1: The effect of imipenem and ceftazidime/amikacin on 
discontinuation of fever for 3 consecutive days 
 
 
 
Discussion 
 
The present study compared the effect of 
imipenem with the standard drug combination of 
ceftazidime/amikacin as an experimental therapy in 
controlling fever and improving clinical and 
microbiological outcomes for confirmed infections and 
unspecified fever in neutropenic cancer patients. 
There was no significant difference between the two 
groups in the rate of discontinuation of fever, 
unmodulated treatment time, or the response of 
patients to bacteremia. After 72 hours from the 
beginning of experimental therapy and body 
temperature measurement and experimental results 
analysis, we found that the clinical and therapeutic 
effect of monotherapy with imipenem as an 
experimental therapy in febrile episodes in patients 
with neutropenic cancers, which was similar to 
combination therapy with ceftazidime/amikacin. It is 
worth noting that imipenem was more effective than 
ceftazidime/amikacin to reduce fever and to improve 
clinical efficacy in cancers with severe fever and 
neutropenia (approximately two times), but there was 
no significant difference between groups due to the 
small number of these patients. 
 The death of one patient (1.6%) occurred on 
imipenem group on the third day. The patient had a 
background of large diffuse b-cell lymphoma. There 
was no positive culture in this patient. It should be 
noted that the patient had severe neutropenia at 
admission. On the third day, the patient suffered from 
abdominal pain and tenderness. During the diagnostic 
evaluations, the patient had an intestinal rupture. 
Furthermore, the patient suffered from a severe fall in 
cardiac blood pressure during surgery, following 
underlying ischemic heart disease and then died. The 
patient's death did not correlate with the drugs used in 
the present study. 
In the present study, after 3 days and 
checking the patient, it was determined that the 
clinical effect of imipenem in the experimental 
treatment of febrile episodes in patients with 
neutropenic cancer is similar to that of 
ceftazidime/amikacin. The level of improvement at the 
end of treatment was similar in both groups. Similarly, 
there was no difference between the two groups in the 
rate of discontinuation of the fever. Finally, unlike the 
available studies, which noted that the gram-positive 
bacteria are the common cause of fever in patients 
with neutropenic cancer, gram-negative organisms 
were more common in the current study. 
Our positive bacterial cultures in 78.9% of 
cases included gram-negative bacteria and in 21% of 
them were gram-positive bacteria. The dominant 
organism was gram negative. E. coli was the most 
commonly isolated organism. All isolated gram-
positive bacteria were resistant to our antibiotics. All 
Gram-negative bacteria were sensitive to imipenem 
and ceftazidime, while 28.5% of gram-negative 
bacteria isolated from the blood were resistant to 
amikacin. Both P. aeruginosa and two E. coli blood 
cultures were resistant to amikacin. No urine culture 
showed resistance to amikacin. Imipenem was more 
effective than ceftazidime/amikacin in reducing fever 
and improving clinical symptoms of patients with and 
without bacteriological confirmation. However, there 
was no significant difference between the two groups. 
Both drugs were more effective in patients with 
bacteriological confirmation than patients without 
bacteriological confirmation. However, there was no 
significant difference between the two groups. 
There was no difference in drug tolerance in 
the two groups, and no drug complications were seen 
in the two groups. It is very important that in the 
present study, none of the patients died due to gram-
negative sepsis, which indicated the strength of both 
drug regimens including imipenem monotherapy and 
ceftazidime/amikacin combination therapy against 
gram-negative bacteria. All gram-negative bacteremia 
responded to our drugs without adding additional 
antibacterial agents. However, the bacteremia 
induced by gram-positive pathogens showed a very 
poor response to treatment in both groups. 
There was no significant difference in drug 
tolerance in the two groups, and no side effects were 
seen in the two groups. On the other hand, the poor 
clinical effect of imipenem and ceftazidime/amikacin 
on gram-positive bacteremia in recent studies 
suggests that there is no reason to delay the addition 
of glycopeptides such as vancomycin to imipenem 
and ceftazidime/amikacin following a lack of clinical 
response after 72 hours of treatment. 
Medication modification has occurred in 9.8% 
of the imipenem group and 16.3% of the 
ceftazidime/amikacin group. The higher response to 
imipenem compared to ceftazidime/amikacin may be 
due to a wider range of coverage against uncommon 
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pathogens or resistant pathogens; however, more 
studies are needed for this. Various studies have 
been conducted since 1992, with conflicting results 
from the effects of these drugs. A study has shown 
that the use of imipenem in the treatment of fever and 
neutropenia has been more effective than 
combination therapy of ceftazidime/amikacin [23]. 
Ronald and colleagues have shown that the 
rate of successful clinical response at the end of 
unmodified treatment was higher in the imipenem 
group (43%) than ceftazidime group (32%). 
Meropenem was significantly more effective in 
neutropenia below 100 cells/μl than ceftazidime [27]. It 
has been indicated that meropenem monotherapy has 
been well tolerated and produced response rates 
similar to those obtained with ceftazidime/amikacin. 
The least success rate in both methods was 
consistent with other recent studies and was probably 
associated with a combination of several factors, 
including the adoption of strict evaluation criteria [20]. 
Concerning the efficacy of meropenem in comparison 
with combination therapy with ceftazidime and 
amikacin, there has been no statistically significant 
difference between the two groups in the efficacy of 
these drugs [23]. 
It has been shown that single-agent therapy 
with ceftazidime or imipenem can be effectively 
suitable for the experimental treatment of febrile 
episodes in patients with neutropenia and solid 
tumours. Early addition of amikacin or vancomycin 
could provide an opportunity for treatment in the first 
step [25]. 
Another study has reported that monotherapy 
with meropenem, can lead to suitable treatment of 
fever in patients with granulocytopenia cancer, as 
effective as ceftazidime plus amikacin, where both 
regimens have been indicated to be tolerated in the 
mentioned study [28]. Another study found that 
Imipenem/cilastatin and ceftazidime/amikacin 
combination have been shown to be effective in 
treating episodes in neutropenic patients [26]. It has 
been depicted that the patient's response to an 
antibiotic with fever in patients receiving imipenem 
(77%) is significantly better than those receiving 
ceftazidime (56%), especially in patients with 
confirmed microbial infection [24]. A study also 
revealed that there had been no significant difference 
between ceftazidime and Imipenem regimens in 
febrile and neutropenic episodes in patients with 
cancer. It has been suggested that ceftazidime can be 
used as an experimental treatment for fever and 
neutropenia in cancer patients, due to lower prices 
and availability [23]. In one study, it was concluded 
that Gram-negative organisms were more common in 
cancer patients with neutropenic fever undergoing 
chemotherapy, unlike most of the available sources 
that indicated the most commonly reported Gram-
positive agents are causes of fever in these patients 
[29] [30]. 
About the above, the combination regimen of 
ceftazidime/amikacin in the treatment of febrile 
episodes of neutropenic patients can have the same 
effect as imipenem monotherapy. Given the lower 
cost of this therapeutic regimen, it can be a cost-
effective alternative to imipenem. Considering the two-
fold effect of imipenem on the reduction of fever and 
the improvement of clinical symptoms in patients with 
severe fever and neutropenia compared to the 
combination of ceftazidime/amikacin and no 
significant difference between the two groups, it 
seems that the low number of these patients were 
associated with current results. It is recommended 
that a study is conducted with a larger sample size or 
a study in which only patients with severe neutropenia 
be studied. The current was performed for 3 days, and 
the patients were followed up for 4 days after the 
discontinuation of the fever or 7 days. Patients were 
not followed up after the study period, and no 
information was available on the return of the fever, 
the incidence of fatalities, the improvement of severe 
neutropenia, and the death rate of the patients after 
the Study period. It is therefore recommended that a 
similar study is conducted with a longer follow-up of 
the patients. We recommend that the standardisation 
of laboratory and microbiological tools be considered 
for better results. Considering the limited studies in 
this area and different microbial flora in each region, it 
can be recommended that similar studies be carried 
out in each region, followed by determination of the 
predominant microbial flora in neutropenic febrile 
patients and measurement of the sensitivity and 
resistance of the organism to this antibiotic. Because 
of the contradiction in the definition of "response" in 
various studies, comparing the results of this study 
with other studies in the evaluation of experimental 
antibiotic therapy in febrile neutropenia is difficult. 
However, the results of neutropenic studies are 
affected by the definition of "response", especially 
when the response rate of two or more antibiotic 
regimens is compared. The final choice of 
experimental antibiotic regimen for use in the 
treatment centre should be based on the antimicrobial 
resistance patterns of each region. 
In conclusion, the results of our study showed 
that imipenem and ceftazidime/amikacin are both 
effective in the initial experimental treatment of febrile 
neutropenic patients, and both are well tolerated. 
Results should be interpreted with caution in the 
absence of confirmatory studies in a specific subgroup 
of patients.  
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